Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients

Jemal, 2015, Cancer statistics, 2015, CA Cancer J Clin, 65, 5, 10.3322/caac.21254

Mottet, Bellmunt, Bolla, Briers, Cumberbatch, De Santis, Fossati, Gross, Henry, Joniau, Lam, Mason, Matveev, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016. https://doi.org/10.1016/j.eururo.2016.08.003.

Karakiewicz, 2006, 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series, J Urol, 176, 569, 10.1016/j.juro.2006.03.094

Walsh, 2001, Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience, Urol Clin North Am, 28, 555, 10.1016/S0094-0143(05)70163-4

Mottet, 2014, EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002

Walsh, 1999, Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, 1591, 10.1001/jama.281.17.1591

Sun, 2015, Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer, Eur Urol, 68, 325, 10.1016/j.eururo.2014.07.020

Sun, 2014, Distribution of metastatic sites in patients with prostate cancer: A population-based analysis, Prostate, 74, 210, 10.1002/pros.22742

Mottet, Briers, Bolla, Cornford, De Santis, Henry, Joniau, Lam, Mason, Matveev, van der Poel, van der Kwast, Rouvière, et al. EAU - ESTRO - SIOG Guidelines on Prostate Cancer. European Association of Urology. 2016.

Seitz, 2013, 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent, Eur Urol, 63, 792, 10.1016/j.eururo.2012.08.003

Trovo, 2006, [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients, Eur J Nucl Med Mol Imaging, 33, 1387, 10.1007/s00259-006-0150-2

Langsteger, 2006, Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?, Mol Imaging Biol, 8, 43, 10.1007/s11307-005-0023-2

Verburg, 2016, Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT, Eur J Nucl Med Mol Imaging, 43, 1410, 10.1007/s00259-016-3366-9

Schwaiger, 2008, The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer, Eur J Nucl Med Mol Imaging, 35, 18, 10.1007/s00259-007-0581-4

Gschwend, 2016, Current use of PSMA-PET in prostate cancer management, Nat Rev Urol, 13, 226, 10.1038/nrurol.2016.26

Zechmann, 2013, PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, Eur J Nucl Med Mol Imaging, 40, 486, 10.1007/s00259-012-2298-2

Herlemann, Wenter, Kretschmer, Thierfelder, Bartenstein, Faber, Gildehaus, Stief, Gratzke, Fendler. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Eur Urol. 2016. https://doi.org/10.1016/j.eururo.2015.12.051.

Rauscher, Maurer, Beer, Graner, Haller, Weirich, Doherty, Gschwend, Schwaiger, Eiber. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016. https://doi.org/10.2967/jnumed.116.173492.

Perera, Papa, Christidis, Wetherell, Hofman, Murphy, Bolton, Sensitivity. Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016. https://doi.org/10.1016/j.eururo.2016.06.021.

Schwaiger, 2015, Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy, J Nucl Med, 56, 668, 10.2967/jnumed.115.154153

Stief, 2015, Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy, J Urol, 193, 484, 10.1016/j.juro.2014.08.096

Kwon, 2015, Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography, J Urol, 193, 111, 10.1016/j.juro.2014.08.082

Briganti, 2015, Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years, Eur Urol, 67, 299, 10.1016/j.eururo.2014.02.011

Schultze-Seemann, 2012, Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer, J Urol, 188, 2190, 10.1016/j.juro.2012.08.041

Haberkorn, 2014, Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 41, 11, 10.1007/s00259-013-2525-5

Kropf, 2016, 68Ga-PSMA-PET/CT in Patients with Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT, Clin Nucl Med, 41, 515, 10.1097/RLU.0000000000001197

Touijer, 2015, Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy, Eur Urol, 67, 839, 10.1016/j.eururo.2014.03.019

Cornford, Bellmunt, Bolla, Briers, De Santis, Gross, Henry, Joniau, Lam, Mason, van der Poel, van der Kwast, Rouviere, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016. https://doi.org/10.1016/j.eururo.2016.08.002.

Eiber, 2015, Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer, Eur Urol, 68, 530, 10.1016/j.eururo.2015.04.034

Fendler, Schmidt, Wenter, Thierfelder, Zach, Stief, Bartenstein, Kirchner, Gildehaus, Gratzke, Faber. 68Ga-PSMA-HBED-CC PET/CT detects location and extent of primary prostate cancer. J Nucl Med. 2016. https://doi.org/10.2967/jnumed.116.172627.

Clavien, 2004, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 240, 205, 10.1097/01.sla.0000133083.54934.ae